Abstract: The morbidity of malignant tumor continues to increase globally. But, thanks to the therapeutic advances in oncology, there is a decreasing trend in mortality. However, with the prolonged survival of tumor patients, the short- and long-term adverse effects of anticancer therapies have increased significantly, especially the treatment of cardiovascular toxicity has become a focus of relevant studies. Cancer survivors may be at a higher risk of new or worsening cardiovascular problems than tumor recurrence. In this article, we review the emerging data on the current status and research progress of anticancer-related cardiovascular toxicity.